![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
VIR-2218 Plus VIR-3434 Combination Therapy Reduces Hepatitis B Virus Surface Antigen Levels In Vivo
|
|
|
EASL 2022 June 22-26 London
Julia Noack,1 Jonathan Gall,1a Hasan Imam,1 Yesseinia Anglero-Rodriguez,2 Vasant Jadhav,2 Michael A. Schmid,3 Anna I. Bakardjiev,1a Lisa A. Purcell,1 Christy Hebner,1 Florian A. Lempp1
1Vir Biotechnology, San Francisco, CA, USA; 2Alnylam Pharmaceuticals, Cambridge, MA, USA; 3Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
aAffiliation at time of study.
![0705221](../images/070522/070522-9/0705221.gif)
![0705222](../images/070522/070522-9/0705222.gif)
![0705223](../images/070522/070522-9/0705223.gif)
![0705224](../images/070522/070522-9/0705224.gif)
![0705225](../images/070522/070522-9/0705225.gif)
![0705226](../images/070522/070522-9/0705226.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|